Dr. RR Baliga's 'Podkast for the Kurious Doc'
A quiet shift, yet a profound one. 🧠 The OCEANIC-STROKE trial introduces asundexian, a Factor XIa inhibitor that lowers recurrent ischemic stroke risk (HR 0.74) without increasing major bleeding—a long-sought balance in antithrombotic therapy. For decades, we traded efficacy for safety. Now, we may finally have both. ⚖️ The implications extend beyond stroke—to a broader rethinking of thrombosis itself: can we uncouple clot from bleed? This study suggests we can. #StrokePrevention #Cardiology #Neurology #ClinicalTrials #Anticoagulation...
info_outlineDr. RR Baliga's 'Podkast for the Kurious Doc'
🧠 Brain metastases remain a clinical frontier—common, complex, and still lethal. In Science Signaling, Chafe et al. unpack the biology: Blood Brain Barrier traversal, metabolic rewiring, and immune evasion. Key insight: metastasis is not just spread—it is adaptation. From adenosine-driven immunosuppression to neuronal-like tumor states, new therapeutic doors are opening. Precision oncology must now think beyond the primary tumor. #BrainMetastases #Oncology #NeuroOncology #Immunotherapy #PrecisionMedicine
info_outlineDr. RR Baliga's 'Podkast for the Kurious Doc'
What if the roots of modern surgery were written over 2,000 years ago? 🩺📜 Meet —a pioneer whose Suśruta Saṃhitā laid the foundations of plastic surgery, cataract procedures, and structured medical training. From rhinoplasty to hands-on simulation using natural models, his approach was remarkably ahead of its time. A reminder that innovation is often rediscovery—and that the future of medicine is deeply anchored in its past. 🌍✨ #HistoryOfMedicine #Ayurveda #Surgery #MedicalEducation #Innovation
info_outlineDr. RR Baliga's 'Podkast for the Kurious Doc'
🧠💊 Stop. Test. Rethink. A compelling new study in JAMA shows that ~26% of adults ≥60 years can safely discontinue levothyroxine, maintaining normal thyroid function—especially those on low doses (≤50 μg/day). 📉 No meaningful decline in quality of life 📊 Clear dose-response signal ⚠️ Raises concerns about lifelong overtreatment The message is elegant: Not every prescription deserves permanence. Time to reassess, deprescribe, and individualize—particularly in our older patients. #Thyroid #Endocrinology #Deprescribing #Geriatrics...
info_outlineDr. RR Baliga's 'Podkast for the Kurious Doc'
A fascinating step forward in Nature—where immunology meets cardiology. 🧬❤️ This study shows that engineered dendritic cells can locally reprogram the immune response, reduce fibrosis, and improve cardiac function—without systemic immunosuppression. The insight is simple, yet profound: 👉 Heart failure is not just hemodynamic—it is immunologic. From FAP-targeted delivery to checkpoint-mediated tolerance (PD-L1, CTLA4-Ig, IL-10), this work opens the door to a new therapeutic paradigm—precision immunotherapy for heart failure. 🚀 The seeds of...
info_outlineDr. RR Baliga's 'Podkast for the Kurious Doc'
🧠⏳ Age. Biology. Truth. A compelling Perspective in the New England Journal of Medicine challenges one of medicine’s quiet assumptions: that age equals risk. Two patients may share a birth year—but not a biology. From epigenetic clocks to physiological reserve, the evidence is clear: chronologic age is an imperfect proxy for clinical decision-making ⚠️ The consequence? Missed prevention in the young, withheld therapy in the old. ✨ The opportunity? A shift toward biologically grounded, precision care—where treatment aligns not with years lived,...
info_outlineDr. RR Baliga's 'Podkast for the Kurious Doc'
Why do GLP-1 therapies transform some patients—and barely move the needle in others? 🧬💉 A recent Nature study (~28,000 participants) identifies GLP1R and GIPR variants linked to both weight loss efficacy and GI side effects. 📊 Signal: modest for weight loss, stronger for tolerability 🧠 Insight: genetics + clinical factors explain ~25% variability 🚀 Implication: early steps toward precision obesity therapeutics The future may not be “one drug fits all,” but one genome, one strategy.
info_outlineDr. RR Baliga's 'Podkast for the Kurious Doc'
Master athletes challenge one of medicine’s most elegant assumptions: that fitness always protects. In the Journal of the American College of Cardiology (JACC) consensus statement on athletes with abnormal cardiovascular findings, a paradox emerges—higher fitness, yet distinct patterns of risk: atrial fibrillation, coronary calcium, myocardial fibrosis. The lesson is not to discourage exercise—but to refine our lens. For the clinician: risk stratification must be individualized. For the athlete: performance and prudence must coexist. 🏃♂️ The heart...
info_outlineDr. RR Baliga's 'Podkast for the Kurious Doc'
A compelling study in : sustained moderate-to-vigorous physical activity across midlife is associated with a ~50% reduction in all-cause mortality in women (target trial emulation). Not intensity, not intermittence—consistency is the signal. For clinicians, the prescription is enduring: move often, move steadily, move for life. 🏃♀️💓 #PLOSMedicine #PreventiveCardiology #LifestyleMedicine #HealthyAging
info_outlineDr. RR Baliga's 'Podkast for the Kurious Doc'
The origins of medicine are not merely scientific—they are deeply philosophical. In our Great Doctors Series, we begin with Dhanvantari, the divine physician of Ayurveda, emerging from myth into method. From the Ocean of Milk to the clinics of today, this episode explores how healing began as a sacred science. For students and physicians alike, it is a reminder that medicine is not just practiced—it is inherited, refined, and reimagined across centuries. 🌿🩺✨ 🎬 “Before medicine became a science, it was a gift—from the gods to humanity.”
info_outlineType 1 Diabetes is more than high sugar — it is autoimmunity, absolute insulin deficiency, and lifelong vigilance. 🧬💉
Early recognition of polyuria, polydipsia, and weight loss can prevent diabetic ketoacidosis. Timely diagnosis with islet autoantibodies and C-peptide testing guides care. 📊
Modern insulin strategies and continuous glucose monitoring have transformed outcomes — yet microvascular and macrovascular risks remain.
Precision, persistence, partnership. 🩺